Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
<Inclusion Criteria>
Newly diagnosed pediatric/adolescent acute lymphomblastic leukemia patient with NCL standard risk that stratifies all 1-4 of following
A. Kidney function (satisfies i or ii) i. Creatinine clearance (or radioisotope-measured GFR) ≥ 70mL/min/1.73m2 ii. Creatinine value according to age/sec satisfies the following:
1 to < 2 years: Male: 0.6 / Female: 0.6, 2 to < 6 years: Male: 0.8 / Female: 0.8, 6 to < 10 years: Male: 1 / Female: 1, 10 to < 13 years: Male: 1.2 / Female: 1.2, 13 to < 16 years: Male: 1.5 / Female: 1.4, ≥ 16 years: Male: 1.7 / Female: 1.4 However, subjects who meet the selection criteria within 1 week before registration after receiving appropriate conservative treatment, including fluid therapy, can be registered.
B. Liver function i. Direct bilirubin < 3.0mg/dL
<Exclusion Criteria>
heeyoung.ju@samsung.com82-2-3410-0865
hjds.shin@samsung.com82-2-3410-6763
Seoul, Other (Non U.s.) 03174, South Korea
taban@hanmail.net82-2-3010-3373
heeyoung.ju@samsung.com82-2-3410-0865
hjds.shin@samsung.com82-2-3410-6763
41sirius@hanmail.net+82-10-6478-8489
phojyk@knu.ac.kr+82-53-200-5704
heagori@daum.net82-10-2705-1743
swan93@naver.com+82-61-379-8060
medyapsb@naver.com+82-64-717-1528
choihs1786@gmail.com+82-31-787-7797
pedonco@korea.ac.kr+82-10-9476-0932
kanghj@snu.ac.kr+82-2-2072-3452
bluenile88@yuhs.ac+82-2-2258-9943
hoiring0209@gmail.com+82-2-2258-6763
juyeon1437@naver.com+82-31-219-5163